Royal Adelaide Hospital, Central Adelaide Local Health Network (CALHN), Adelaide, South Australia, Australia.
School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
ANZ J Surg. 2021 Oct;91(10):2002-2007. doi: 10.1111/ans.16716. Epub 2021 Mar 7.
An under-recognized complication of gelatin-based haemostatic agents is their potential to cause anaphylactic reactions. This review aims to collate and analyse case in the literature of intraoperative anaphylaxis secondary to locally applied haemostatic agents.
An electronic search was performed on databases Medline, Embase, Pubmed and ProQuest. A total of 7671 articles were reviewed from title and abstract. After exclusion criteria and duplicates removed, 19 articles with 21 cases were included for analysis. Data extracted from each of the articles included patient demographics, haemostatic agent used, surgery type, known allergies and any objective evidence of hypersensitivity post anaphylactic episode, that is tryptase levels, IgE levels, skin prick testing.
Fifty-seven percent of cases involved patients <18 years of age; 57% of cases involved spinal surgery; 100% of cases displayed objective evidence of hypersensitivity (tryptase levels, bovine or porcine IgE levels, or skin prick testing). Thirty-three percent of patients had exposure preoperatively to a known agent causing anaphylaxis or allergy which would preclude the use of a gelatin-based haemostat. These products included vaccines, spam meats, red meat, Jell-O and CollaPlug. Gelatin-based haemostat agents included Floseal, Gelfoam, Surgiflo, fibrin glue, Avitene, haemofibrine sponge, topical bovine thrombin and thrombin-soaked gelatin.
Increased awareness of allergy to gelatin-based haemostats for surgical and anaesthetic is imperative, with 33% of cases having a known contraindication to gelatin-based haemostat. This review highlights important aspects in the pre-operative patient history and post-event patient investigation that could assist anaesthetists and surgeons in the prevention of future events.
明胶基止血剂的一个未被充分认识的并发症是它们有可能引起过敏反应。本综述旨在收集和分析文献中局部应用止血剂引起术中过敏反应的病例。
在 Medline、Embase、Pubmed 和 ProQuest 数据库中进行电子检索。从标题和摘要中审查了 7671 篇文章。在排除标准和重复项后,纳入了 19 篇文章的 21 例进行分析。从每篇文章中提取的数据包括患者人口统计学、使用的止血剂、手术类型、已知过敏症和过敏反应后任何过敏的客观证据,即类胰蛋白酶水平、IgE 水平、皮肤点刺试验。
57%的病例涉及<18 岁的患者;57%的病例涉及脊柱手术;100%的病例显示过敏的客观证据(类胰蛋白酶水平、牛或猪 IgE 水平或皮肤点刺试验)。33%的患者术前接触过导致过敏或过敏的已知药物,从而排除使用明胶基止血剂。这些产品包括疫苗、含有肌肉的肉、红色肉类、果冻和 CollaPlug。明胶基止血剂包括 Floseal、Gelfoam、Surgiflo、纤维蛋白胶、Avitene、纤维蛋白海绵、局部牛凝血酶和凝血酶浸泡的明胶。
提高对手术和麻醉用明胶基止血剂过敏的认识至关重要,33%的病例对明胶基止血剂有已知的禁忌证。本综述强调了术前患者病史和术后患者检查的重要方面,这可以帮助麻醉师和外科医生预防未来的事件。